Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Nutrients ; 13(9)2021 Aug 25.
Article in English | MEDLINE | ID: covidwho-1394978

ABSTRACT

The beverage hydration index (BHI) facilitates a comparison of relative hydration properties of beverages using water as the standard. The additive effects of electrolytes, carbohydrate, and protein on rehydration were assessed using BHI. Nineteen healthy young adults completed four test sessions in randomized order: deionized water (W), electrolytes only (E), carbohydrate-electrolytes (C + E), and 2 g/L dipeptide (alanyl-glutamine)-electrolytes (AG + E). One liter of beverage was consumed, after which urine and body mass were obtained every 60 min through 240 min. Compared to W, BHI was higher (p = 0.007) for C + E (1.15 ± 0.17) after 120 min and for AG + E (p = 0.021) at 240 min (1.15 ± 0.20). BHI did not differ (p > 0.05) among E, C + E, or AG + E; however, E contributed the greatest absolute net effect (>12%) on BHI relative to W. Net fluid balance was lower for W (p = 0.048) compared to C + E and AG + E after 120 min. AG + E and E elicited higher (p < 0.001) overall urine osmolality vs. W. W also elicited greater reports of stomach bloating (p = 0.02) compared to AG + E and C + E. The addition of electrolytes alone (in the range of sports drinks) did not consistently improve BHI versus water; however, the combination with carbohydrate or dipeptides increased fluid retention, although this occurred earlier for the sports drink than the dipeptide beverage. Electrolyte content appears to make the largest contribution in hydration properties of beverages for young adults when consumed at rest.


Subject(s)
Beverages/analysis , Dehydration/prevention & control , Dietary Carbohydrates/pharmacology , Dietary Proteins/pharmacology , Electrolytes/pharmacology , Water-Electrolyte Balance/physiology , Adult , Dietary Carbohydrates/urine , Dietary Proteins/urine , Double-Blind Method , Electrolytes/analysis , Electrolytes/urine , Female , Humans , Male , Time Factors , Water/administration & dosage , Young Adult
2.
Diabet Med ; 37(7): 1094-1102, 2020 07.
Article in English | MEDLINE | ID: covidwho-116685

ABSTRACT

The month of Ramadan forms one of the five pillars of the Muslim faith. Adult Muslims are obligated to keep daily fasts from dawn to sunset, with exceptions. This year Ramadan is due to begin on 23 April 2020 and the longest fast in the UK will be approximately 18 hours in length. In addition, due to the often high-calorie meals eaten to break the fast, Ramadan should be seen as a cycle of fasting and feasting. Ramadan fasting can impact those with diabetes, increasing the risk of hypoglycaemia, hyperglycaemia and dehydration. This year, Ramadan will occur during the global COVID-19 pandemic. Reports show that diabetes appears to be a risk factor for more severe disease with COVID-19. In addition, the UK experience has shown diabetes and COVID-19 is associated with dehydration, starvation ketosis, diabetic ketoacidosis and hyperosmolar hyperglycaemic state. This makes fasting in Ramadan particularly challenging for those Muslims with diabetes. Here, we discuss the implications of fasting in Ramadan during the COVID-19 pandemic and make recommendations for those with diabetes who wish to fast.


Subject(s)
Diabetes Mellitus, Type 1/therapy , Diabetes Mellitus, Type 2/therapy , Fasting/metabolism , Holidays , Islam , Betacoronavirus , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/metabolism , Dehydration/epidemiology , Dehydration/metabolism , Dehydration/prevention & control , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/metabolism , Diabetic Ketoacidosis/epidemiology , Diet Therapy , Disease Management , Fasting/adverse effects , Fluid Therapy , Humans , Hyperglycemia/epidemiology , Hyperglycemia/metabolism , Hyperglycemia/prevention & control , Hyperglycemic Hyperosmolar Nonketotic Coma/epidemiology , Hyperglycemic Hyperosmolar Nonketotic Coma/metabolism , Hypoglycemia/epidemiology , Hypoglycemia/metabolism , Hypoglycemia/prevention & control , Hypoglycemic Agents/therapeutic use , Ketosis/epidemiology , Ketosis/metabolism , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/metabolism , Risk Assessment , SARS-CoV-2 , United Kingdom
3.
Diabetes Metab Syndr ; 14(4): 405-406, 2020.
Article in English | MEDLINE | ID: covidwho-102280

ABSTRACT

It has been reported that frequent occurrence of COVID-19 infection in these patients is associated with low cytosolic pH. During virus infection, serum lactate dehydrogenase (LDH) level excessively rises. LDH is a cytosolic enzyme and the serum level increases as the cell break down. When anaerobic conditions develop, lactate formation increases from pyruvate. Cell pH is regulated by very complex mechanisms. When lactate increases in the extracellular area, this symporter carries lactate and H+ ion into the cell, and the intracellular pH quickly becomes acidic. Paradoxically, Na+/H+ exchanger activation takes place. While H+ ion is thrown out of the cell, Na+ and Ca+2 enter the cell. When Na+ and Ca+2 increase in the cell, the cells swell and die. Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor. Dapagliflozin has been reported to reduce lactate levels by various mechanisms. Also, it reduces oxygen consumption in tissues and causes the use of glucose in the aerobic pathway, thereby reducing lactate production. A lactate decrease in the environment reduces the activation of lactate/H+ symporter. Thus, the H ion pumping into the cell by this symporter is reduced and the cytosolic pH is maintained. Dapagliflozin also directly inhibits NHE. Thus, Na+ and Ca+2 flow to the cell are inhibited. Dapagliflozin provides the continuation of the structure and functions of the cells. Dapagliflozin can prevent the severe course of COVID-19 infection by preventing the lowering of cytosolic pH and reducing the viral load.


Subject(s)
Benzhydryl Compounds/therapeutic use , Betacoronavirus , Coronavirus Infections/prevention & control , Diabetes Mellitus/drug therapy , Glucosides/therapeutic use , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , COVID-19 , Comorbidity , Coronavirus Infections/epidemiology , Dehydration/prevention & control , Diabetes Mellitus/epidemiology , Humans , Insulin/therapeutic use , Lactic Acid/metabolism , Oxygen Consumption/drug effects , Pneumonia, Viral/epidemiology , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL